In the case of CD19-redirected CAR-T cell therapies, such toxicities result in the elimination of normal B cells, commonly referred to as B-cell aplasia, which consequently places the patients in need of immunoglobulin replacement to circumvent opportunistic infections [65]. This evidence concerns the gene CD19 and Opportunistic infection.